The CHC 2021 Report is Out Now!
Visit the Publications & Media page to access summaries, presentations, and videos on-demand.
About CHC 2021
Join us for the 11th annual Canadian Hematology Conference – Virtual!
CHC 2021 will be held on a virtual streaming platform, running Sept. 30th – Oct. 2nd.
CHC is the largest multi-disciplinary hematological conference across Canada. It brings together a pan-Canadian and International Faculty to showcase cutting-edge research and developments in the field of hematology.
Dr. John Kuruvilla (Princess Margaret Cancer Centre) and Dr. Peter Anglin (Stronach Regional Cancer Centre) will co-chair this event. CHC 2021 is open to Canadian hematology professionals, including residents, nurses, pharmacists, and specialists who have an interest in hematology.
Register to gain access to:
- Leading clinical presentations
- Panelist discussions
- First access to clinical slide decks
- Follow-up Q&A with CHC speakers
- Year-round access to recorded CHC 2021 presentations
Event Details
Date
Day 1 – Thursday, September 30th
Day 2 – Friday, October 1st
Day 3 – Saturday, October 2nd
Chairs
Dr. John Kuruvilla
(Princess Margaret Cancer Centre)
Dr. Peter Anglin
(Stronach Regional Cancer Centre)
AGENDA
Day 1 – Thursday, September 30th
Starting 12:00PM (EST)
Multiple Myeloma
Session Chair: Dr. Peter Anglin (Stronach Regional Cancer Centre)
Optimal Treatment of Relapsed Multiple Myeloma After Standard Induction Failure
Dr. Keith Stewart, Princess Margaret Cancer Centre
Defining & Treating High-Risk Multiple Myeloma
Dr. Saad Usmani, Levine Cancer Institute
Cellular Therapy in Multiple Myeloma
Dr. Noopur Raje, Massachusetts General Hospital
Lunch Symposium
Best Practice in CD30 Testing and Treatment Implementation
Dr. Kerry Savage, BC Cancer & Dr. Graham Slack, BC Cancer
Hodgkin Lymphoma
Session Chair: Dr. John Kuruvilla (Princess Margaret Cancer Centre)
Older Patients with Classical Hodgkin Lymphoma
Dr. John Kuruvilla, Princess Margaret Cancer Centre
Integrating Novel therapy in Second-Line HL
Dr. Alison Moskowitz, Memorial Solan Kettering Cancer Center
Early Stage Classical Hodgkin Lymphoma
Dr. Graham Collins, Oxford Cancer and Haematology Centre
Radiation Therapy in Upfront Management of Hodgkin Lymphoma
Dr. David Hodgson, Princess Margaret Cancer Centre
Day 2 – Friday, October 1st
Starting 12:00PM (EST)
Non-Hodgkin Lymphoma 1
Current and Novel Therapy in RR-DLBCL
Dr. Gilles Salles, Memorial Solan Kettering Cancer Center
Central Nervous System Prophylaxis in DLBCL
Dr. Christopher Fox, Nottingham University Hospitals
Management of Frontline PTCL
Dr. Steven M. Horwitz, Memorial Solan Kettering Cancer Center
The Role of Radiation in Diffuse Large B-Cell Lymphoma in 2021
Dr. Danielle Rodin, Princess Margaret Cancer Centre
Chronic Lymphocytic Leukemia
Session Chair: Dr. Verhsa Banerji (Cancer Care Manitoba)
Treatment of CLL – From a Canadian Perspective
Dr. Versha Banerji, Cancer Care Manitoba
State of the Art Management in Relapsed Refractory CLL
Dr. Anthony Mato, Memorial Solan Kettering Cancer Center
Frontline CLL
Dr. Susan O’Brien, UC Irvine
Non-Hodgkin Lymphoma 2
Session Chair: Dr. Diego Villa (BC Cancer)
Current and Novel Therapy in RR-FL
Dr. Sonali Smith, University of Chicago Medicine
CAR T-cell Therapy: Mantle Cell and Follicular Lymphoma
Dr. Caron Jacobson, Dana Farber Cancer Institute
Maintenance Therapy in Indolent Lymphoma
Dr. Diego Villa, BC Cancer
Day 3 – Saturday, October 2nd
Starting 10:00AM (EST)
Myeloid
Session Chair: Dr. Vikas Gupta (Princess Margaret Cancer Centre)
Updates in Myelodysplastic Syndromes
Dr. Mikkael Sekeres, Sylvester Comprehensive Cancer Centre
Novel Approaches Including Non-Intensive Induction in AML
Dr. Guillaume Richard-Carpentier, Queen’s University
Clinical Updates in Myeloproliferative Neoplasms
Dr. Mrinal Patnaik, Mayo Clinic
Challenges in Hematology
Challenges of Older Patients
Dr. Stefano Luminari, University of Modena and Reggio Emilia
Intersectionality in Haematology
Dr. Nada Hamad, St. Vincent’s Hospital Sydney
Covid 19 vaccination in CLL and Heme Malignancies
Dr. Gwen Nichols, Leukemia & Lymphoma Society (LLS)
